Status:
COMPLETED
Leptin Infusion and Endothelial Vasomotor Response
Lead Sponsor:
Stefan Soderberg
Collaborating Sponsors:
University of Edinburgh
Conditions:
Endothelial Dysfunction
Obesity
Eligibility:
All Genders
Phase:
EARLY_PHASE1
Brief Summary
Adipose tissue is an active endocrine organ producing several hormones with circulatory and metabolic effects. In 1994, the hormone leptin was discovered. The lack of this hormone explained extreme ob...
Detailed Description
Introduction High BMI and particularly fat mass index are associated with increased risk of coronary artery disease and other cardiovascular conditions, but the underlying mechanisms are not well unde...
Eligibility Criteria
Inclusion
- Inclusion criteria protocol 1 and 2;
- Healthy male
- No regular medication
- Non-smoking
- Abstain from alcohol for 24 hours and from food, tobacco and caffeine-containing drinks for at least 4 hours before each study visit
- Inclusion criteria protocol 3;
- Established coronary artery disease
- Stable angina pectoris
- Documented ≥ 50% stenosis of at least one major epicardial coronary vessel
- Exclusion criteria protocol 3;
- Coronary revascularisation within three months
- Diabetes mellitus
- Cardiac failure (ejection fraction \<35% or New York Heart Association (NYHA) ≥2)
- Renal impairment (creatinine ≥200 µmol/L)
- Systolic blood pressure \<100 or \>190 mmHg
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2006
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT04374500
Start Date
January 1 2006
End Date
December 20 2006
Last Update
May 9 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Umeå University Hopsital
Umeå, Sweden, 90185
2
British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh
Edinburgh, United Kingdom